Glenmede Trust’s Juno Therapeutics, Inc. JUNO Stock Holding History

Glenmede Trust’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-156	Closed	-$7K	–	2515
2018 Q1	$7K	Hold	156	–	–	﹤0.01%	2332
2017 Q4	$7K	Hold	156	–	–	﹤0.01%	2332
2017 Q3	$6K	Buy	+156	New	+$5.32K	﹤0.01%	2332
2017 Q1	–	Sell	-150	Closed	-$2K	–	2815
2016 Q4	$2K	Buy	+150	New	+$3.67K	﹤0.01%	2372
2016 Q1	–	Sell	-200	Closed	-$8K	–	2789
2015 Q4	$8K	Hold	200	–	–	﹤0.01%	2150
2015 Q3	$8K	Hold	200	–	–	﹤0.01%	2179
2015 Q2	$10K	Hold	200	–	–	﹤0.01%	2113
2015 Q1	$12K	Hold	200	–	–	﹤0.01%	2097
2014 Q4	$10K	Buy	+200	New	+$8.95K	﹤0.01%	2215

Glenmede Trust's JUNO Position: Q2 2018 in Review

Glenmede Trust sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2018, closing a stake of 156 shares — an estimated $7K sold.

Glenmede Trust first reported a position in JUNO in Q4 2014 and held it in 9 quarters. The position peaked at $12K in Q1 2015. 0 funds tracked by Wall St. Rank hold JUNO as of Q2 2018.

Glenmede Trust reported no remaining Juno Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Glenmede Trust sold 156 Juno Therapeutics, Inc. shares in Q2 2018, an estimated $7K.
Glenmede Trust first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 9 quarters.
Glenmede Trust's Juno Therapeutics, Inc. position peaked at $12K in Q1 2015.
0 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2018.

Based on Glenmede Trust's 13F filing for Q2 2018, filed 15 Aug 2018.